We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Expert: Firms Should Scrutinize FDA Risk Management Guidances
Expert: Firms Should Scrutinize FDA Risk Management Guidances
June 10, 2005
Pharmaceutical firms should be prepared to justify their decisions not to follow recommendations in the FDA’s recent guidances on minimizing drug-safety risks, say experts, who warn the nonbinding suggestions could be used against firms in court.